Does a permanent exit from GLP-1 drugs exist without losing the weight?

Fractyl Health has released one-year data that challenge the assumption that weight loss maintenance demands lifelong medication. Patients who lost an average of 24% of their body weight on GLP-1 drugs underwent a single Revita procedure—a minimally invasive endoscopic intervention that remodels the duodenum, the first section of the small intestine—and retained 78% of their weight loss at twelve months, compared to the typical 15% rebound after discontinuing these drugs alone. The mechanism is elegantly straightforward: Revita restores healthy metabolic signaling in the duodenum, reframing the intestine not as a simple digestive tube but as a metabolic control center governing appetite, insulin sensitivity, and systemic energy balance. Notably, 33% of participants continued losing weight after stopping medication, and the procedure reported no serious adverse events, only mild discomfort resolving in the first month. For the longevity-focused reader, this convergence of durable intervention and liberation from chronic treatment represents a conceptual shift: this is not about replacing Ozempic, but answering the question patients have asked for years—must I inject weekly for life?—with an option that addresses the biological root of metabolism rather than perpetuating pharmaceutical dependency.